Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project-Reference-Cited by-同舟云学术

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Published:2024-08-06 Issue:5 Volume:19 Page:747-755
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Rizzo Alessandro^ORCID,Monteiro Fernando Sabino Marques,Ürün Yüksel,Massari Francesco,Park Se Hoon,Bourlon Maria T.,Poprach Alexandr,Rizzo Mimma,Takeshita Hideki,Giannatempo Patrizia,Soares Andrey,Roviello Giandomenico,Molina-Cerrillo Javier,Carrozza Francesco,Abahssain Halima,Messina Carlo,Kopp Ray Manneh,Pichler Renate,Formisano Luigi,Tural Deniz,Atzori Francesco,Calabrò Fabio,Kanesvaran Ravindran,Buti Sebastiano,Santoni Matteo

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01089-2.pdf

Reference26 articles.

1. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–7. https://doi.org/10.1172/JCI83871.

2. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. https://doi.org/10.1038/s41467-020-17670-y.

3. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86. https://doi.org/10.1016/S0140-6736(20)32714-8.

4. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643.

5. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.